⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PMN News
ProMIS Neurosciences Inc. Common Shares (ON)
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference Ready to Announce with Confidence?
newsfilecorp.com
PMN
Form 8-K
sec.gov
PMN
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
globenewswire.com
PMN
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
globenewswire.com
PMN
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
PMN
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
globenewswire.com
PMN
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
globenewswire.com
PMN
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
globenewswire.com
PMN
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
globenewswire.com
PMN
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
globenewswire.com
PMN